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TaiwanAbstractThe clinical characteristics of patients with colistin-resistant Acinetobacter baumannii bacteraemia have been documented, but those of patients
with bacteraemia caused by other Acinetobacter species remain unknown. Previous exposure to colistin has been shown to be associated with
the emergence of colistin resistance, but may be not the only predisposing factor. In the current study, we highlight the risk and outcome of
patients without previous exposure to colistin who acquired colistin-resistant Acinetobacter nosocomialis (ColRAN) bacteraemia. This 11-year
single-centre retrospective study analysed 58 patients with ColRAN bacteraemia and 213 patients with colistin-susceptible A. nosocomialis
(ColSAN) bacteraemia. Antimicrobial susceptibilities were determined with an agar dilution method. The clonal relationship of ColRAN
isolates was determined with pulsed-ﬁeld gel electrophoresis. A conjugation mating-out assay was conducted to delineate the potential
transfer of colistin resistance genes. Multivariable analysis was performed to evaluate the risk factors for ColRAN bacteraemia. Chronic
obstructive pulmonary disease (COPD) was independently associated with ColRAN bacteraemia (OR 3.04; 95% CI 1.45–6.37; p 0.003).
Patients with ColRAN bacteraemia had higher APACHE II scores, but the two groups showed no signiﬁcant differences in 14-day mortality
(10.3% vs. 10.3%) or 28-day mortality (15.5% vs. 15.0%). ColRAN isolates had greater resistance than ColSAN isolates to all antimicrobial
agents except for ciproﬂoxacin (0% vs. 6.6%). There were 16 different ColRAN pulsotypes, and two major clones were found. Colistin
resistance did not transfer to colistin-susceptible A. baumannii or A. nosocomialis. These results show that COPD is an independent risk
factor for acquisition of ColRAN bacteraemia. The mortality rates were similar between patients with ColRAN and ColSAN bacteraemia.
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p://dx.doi.org/10.1016/j.cmi.2015.05.005IntroductionAcinetobacter species have emerged as signiﬁcant pathogens
associated with severe nosocomial infections [1]. Acinetobacter
baumannii and Acinetobacter nosocomialis, the most clinically
signiﬁcant species, together account for >80% of all Acineto-
bacter infections in Taiwan [2–4]. Although these two speciesious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Wang et al. Colistin-resistant Acinetobacter nosocomialis bacteraemia 759cannot be distinguished by typical phenotypic methods used in
clinical laboratories, they show signiﬁcant differences in terms
of susceptibility to antimicrobial agents and prevalence in epi-
demics [2–5].
The increasing worldwide prevalence of drug resistance,
including carbapenem resistance in Acinetobacter species
[1,3,4,6], has made colistin an important therapeutic option for
infections involving carbapenem-resistant Acinetobacter species
[7–9]. Inappropriate colistin use, however, has led to the
development of colistin-resistant A. baumannii (ColRAB) [8–10]
and colistin resistance in other Gram-negative bacteria [11,12].
Several studies have documented the clinical characteristics of
patients with ColRAB infection [9,11]. In contrast, the risk
factors and clinical impact of colistin-resistant A. nosocomialis
(ColRAN), which is more prevalent than ColRAB [3,4,13,14],
remain unknown. In the current study, we investigated the risks
and outcomes of patients acquiring ColRAN bacteraemia
without previous exposure to colistin. We compared the
characteristics of patients with ColRAN and colistin-susceptible
A. nosocomialis (ColSAN) bacteraemia, and also examined the
antimicrobial susceptibilities and clonal relationships of all
ColRAN isolates.Materials and methodsThis retrospective study was performed at the Taipei Veterans
General Hospital (T-VGH) during an 11-year period
(1998–2008). Data analyses were performed at the Tri-Service
General Hospital (TSGH), National Defense Medical Centre.
Colistin was not used at the T-VGH during the study period.
The study protocol was approved by the T-VGH and TSGH
Institutional Review Boards (approval numbers 2011-10-
012IC and 2-101-05-074, respectively), with a waiver for
informed consent because the study was retrospective.
Chart review was performed for patients who had at least
one positive blood culture for A. nosocomialis with symptoms
and signs of infection. For patients with two or more positive
blood cultures, only the ﬁrst blood culture was included. The
source of infection was determined according to CDC guide-
lines [15]. Patients with polymicrobial bacteraemia (isolation of
one or more microorganisms other than A. nosocomialis from
blood during the same bacteraemia episode) were excluded. A
bacteraemia case without a deﬁnite identiﬁed source was
deﬁned as primary bacteraemia. Patients aged <18 years and
those with incomplete medical records were excluded.
Data collection
Medical records were reviewed to extract demographic and
clinical information, including underlying diseases, admission toClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologythe intensive-care unit, duration of hospitalization, schedule and
dose of antimicrobials, receipt of mechanical ventilation, and
infectious foci. Chronic kidney disease was deﬁned as an esti-
mated glomerular ﬁltration rate of <60 mL/min/1.73 m2. Neu-
tropenia was deﬁned as an absolute neutrophil count of
<0.5 × 109 cells/L. Use of corticosteroids was deﬁned as receipt
of a corticosteroid at a dose greater than or equal to 10 mg per
day of prednisolone for >5 days in the 4-week period prior to the
onset of bacteraemia. Previous use of antibiotics was deﬁned as
antimicrobial therapy (intravenous or oral) within 4 weeks
before onset of bacteraemia. Recent surgery was deﬁned as
operations performed within 4 weeks prior to the onset of
bacteraemia. The severity of illness was evaluated according to
the Acute Physiology and Chronic Health Evaluation II (APACHE
II) score within 24 h before the onset of bacteraemia.
Appropriate antimicrobial therapy was deﬁned as adminis-
tration of at least one antimicrobial agent to which the causative
pathogen was susceptible within 48 h after the onset of bacter-
aemia, with the approved route and dosage for the affected end
organ(s). Antimicrobial therapy that did not meet this deﬁnition
was considered to be inappropriate. Monotherapy with an ami-
noglycoside was considered to be inappropriate therapy.
Microbiological studies
Bacterial isolates were phenotypically identiﬁed as members of
the Acinetobacter calcoaceticus–baumannii complex with the API
ID 32 GN system or the Vitek 2 system (both from bioMérieux,
Marcy l’Etoile, France). A. nosocomialis was identiﬁed by
sequencing the 16S–23S ribosomal DNA intergenic spacer
region [16]. Antimicrobial susceptibility testing was performed
with an agar dilution method according to the guidelines of the
CLSI [17]. Colistin resistance was deﬁned by the presence of a
MIC of at least 2 mg/L.
Molecular typing
The clonal relationship of clinical isolates was determined by
pulsed-ﬁeld gel electrophoresis (PFGE) [18] of ApaI-digested
genomic DNA with the Bio-Rad CHEF-Mapper apparatus (Bio-
Rad Laboratories, Hercules, CA, USA). Cluster analysis was
performed with BioNumerics version 5.0 (Applied Maths, Sint-
Martens-Latem, Belgium) and the unweighted pair-group
method with arithmetic averages. The Dice correlation coefﬁ-
cient (tolerance: 1%) was used to analyse similarities between
band patterns. Isolates were considered to be different pulso-
types if they had more than three DNA fragment differences
and a similarity of <80% in dendrogram analysis.
Conjugation experiments
Conjugation experiments were performed to determine
whether the colistin resistance genes can be transferred fromand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 758–764
TABLE 1. Demographic and clinical characteristics of patients
with bacteraemia caused by Acinetobacter nosocomialis
Demographic or characteristic
Colistin
resistant
(n [ 58)
Colistin
susceptible
(n [ 213) p
Age (years), mean ± SD 68.5 ± 21.2 66.9 ± 16.5 0.593
Male gender, no. (%) 44 (75.9) 118 (55.4) 0.343
Acquired in the
intensive-care unit, no. (%)
44 (75.9) 102 (47.9) <0.001
Infection source, no. (%)
Respiratory tract 40 (69.0) 87 (40.9) <0.001
Primary bacteraemia 5 (8.6) 68 (31.9) <0.001
Intravenous device 6 (10.3) 21 (9.9) 0.913
Intra-abdominal 1 (1.7) 16 (7.5) 0.107
Urinary tract 2 (3.5) 10 (4.7) 0.682
Soft tissue or wound 4 (6.9) 9 (4.2) 0.399
Comorbidity, no. (%)
Cerebral vascular disease 10 (17.2) 42 (19.7) 0.671
Chemotherapy 2 (3.5) 35 (16.4) 0.011
Chronic kidney disease 10 (17.2) 37 (17.4) 0.982
Chronic obstructive
pulmonary disease
19 (32.8) 25 (11.7) <0.001
Coronary artery disease 8 (13.8) 37 (17.4) 0.516
Congestive heart failure 9 (15.5) 19 (8.9) 0.143
Collagen vascular disease 1 (1.7) 9 (4.2) 0.370
Hypertension 13 (22.4) 73 (34.3) 0.085
Liver cirrhosis 4 (6.9) 13 (6.1) 0.825
Neutropenia 2 (3.5) 6 (2.8) 0.801
Peripheral artery
occlusive disease
0 (0.0) 6 (2.8) 0.196
Malignancy
Haematological malignancy 2 (3.5) 12 (5.6) 0.505
Solid malignancy 18 (31.0) 83 (39.0) 0.268
Corticosteroid use 8 (13.8) 42 (19.7) 0.302
Surgery within 1 month 28 (48.3) 76 (35.7) 0.140
Type 2 diabetes mellitus 16 (27.6) 52 (24.4) 0.621
Respiratory failure under
mechanical ventilation,a no. (%)
43 (74.1) 87 (40.8) <0.001
Previous antibiotic exposure, no. (%) 38 (65.5) 88 (41.3) 0.001
Days of hospitalization prior
to culture (days), median (IQR)
56 (32–101) 37 (22–65) <0.001
APACHE II score,b median (IQR) 21 (17–28) 18 (14–25) 0.007
Appropriate antimicrobial
therapy, no. (%)
27 (46.6) 111 (52.1) 0.453
Mortality, no. (%) 21 (36.2) 84 (39.4) 0.654
14-day mortality 6 (10.3) 22 (10.3) 0.997
760 Clinical Microbiology and Infection, Volume 21 Number 8, August 2015 CMIColRAN to A. baumannii and ColSAN [19]. For these exper-
iments, we randomly selected four representative ColRAN
isolates that were susceptible to imipenem and ceftazidime
from different pulsotypes as donors, and one colistin-
susceptible but imipenem-resistant A. baumannii (ColSAB)
isolate and two ColSAN isolates that were resistant to cef-
tazidime as recipients. The mating-out assays were performed
on Müller–Hinton agar plates, with the ﬁlter mating technique,
at 37°C. Transconjugants were selected on brain–heart infu-
sion agar plates that contained colistin plus imipenem or cef-
tazidime. Species identiﬁcation of transconjugants was
performed with multiplex PCR ampliﬁcations, as previously
described [20].
Statistical analysis
The chi-square test with Yate’s correction or Fisher’s exact test
was used to compare discrete variables, and Student’s t-test or
the Mann–Whitney rank sum test were used to compare
continuous variables. Univariate analyses were performed
separately for each risk factor to determine the OR and 95% CI.
All biologically plausible variables with p-values of 0.10 in the
univariate analysis and present in at least 10% of the patients
were included in the logistic regression model for multivariate
analysis, which employed a backward selection process. A p-
value of <0.05 was considered to be statistically signiﬁcant. All
statistical analyses were performed with SPSS software, version
19.0 (SPSS, Chicago, IL, USA).28-day mortality 9 (15.5) 32 (15.0) 0.926
APACHE II, Acute Physiologic and Chronic Health Evaluation II; IQR, interquartile
range; SD, standard deviation.
aUnder mechanical ventilation support for >48 h prior to bacteraemia onset.Results
bWithin 24 h prior to bacteraemia onset.During the 11-year study period, 891 patients at our institution
experienced at least one episode of A. calcoaceticus–baumannii
complex bacteraemia; of these, 348 patients (39.1%) also
experienced at least one episode of A. nosocomialis bacteraemia.
Of these 348 patients, we excluded 77 patients (22.1%) with
polymicrobial bacteraemia. The remaining 271 patients were
included in the ﬁnal analysis.
Table 1 compares the demographic and clinical characteris-
tics of patients with ColRAN bacteraemia (n = 58, 21.4%) and
ColSAN bacteraemia (n = 213, 78.6%). ColRAN bacteraemia
was more strongly associated with infection in an intensive-care
unit (75.9% vs. 47.9%, p < 0.001), longer duration of hospital-
ization before infection (56 vs. 37 days, p < 0.001), use of
mechanical ventilation for >48 h (74.1% vs. 40.8%, p < 0.001),
underlying chronic obstructive pulmonary disease (COPD)
(32.8% vs. 11.7%, p < 0.001), and previous use of an antibiotic
(65.5% vs. 41.3%, p 0.001). In contrast, ColSAN bacteraemia
was more strongly associated with the use of chemotherapy
(3.5% vs. 16.4%, p 0.011). ColRAN bacteraemia was more likelyClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectto originate from pneumonia (69.0% vs. 40.9%, p < 0.001),
whereas ColSAN bacteraemia was more likely to occur as
primary bacteraemia (31.9% vs. 8.6%, p < 0.001). The disease
severity (APACHE II score) was greater in patients with Col-
RAN bacteraemia (21 vs. 18, p 0.007). The frequencies of
appropriate antimicrobial therapy were 46.6% among patients
with ColRAN bacteraemia and 52.1% among those with Col-
SAN bacteraemia (p 0.453). Interestingly, the two groups did
not differ signiﬁcantly with respect to 14-day, 28-day and
overall mortality. Furthermore, among patients with bacter-
aemic pneumonia, those infected with ColRAN and ColSAN
had similar APACHE II scores, 14-day, 28-day and overall
mortality (data not shown), and durations of mechanical
ventilation use (32 vs. 32.5 days, p 0.278).
ColRAN bacteraemia was more strongly associated with the
previous use of an antipseudomonal β-lactam (39.7% vs. 17.8%,
p < 0.001; Table 2), but no other signiﬁcant differences wereious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 758–764
TABLE 2. Antimicrobial agent exposure prior to the onset of
Acinetobacter nosocomialis bacteraemia
Antimicrobial agent
Colistin resistant
(n [ 58), no. (%)
Colistin susceptible
(n [ 213), no. (%) p
Aminoglycosidea 6 (10.3) 23 (10.8) 0.921
Ampicillin–sulbactam
or sulbactam
3 (5.2) 4 (1.9) 0.161
Antipseudomonal
ﬂuoroquinolonesb
1 (1.7) 7 (3.3) 0.533
Antipseudomonal
β-lactamc
23 (39.7) 38 (17.8) <0.001
Non-antipseudomonal
β-lactamd
20 (34.5) 49 (23.0) 0.075
aIncluding gentamicin and isepamicin.
bIncluding ciproﬂoxacin and levoﬂoxacin (both intravenous and oral forms).
cIncluding imipenem, meropenem, cefoperazone, ceftazidime, cefepime, cefpirome,
piperacillin, piperacillin–tazobactam, and ticarcillin–clavulanate.
dIncluding ampicillin, amoxycillin, amoxycillin–clavulanate, cefazolin, cefuroxime, cefo-
taxime, ceftriaxone, ﬂomoxef, and penicillin.
TABLE 4. Antimicrobial susceptibilities of clinical isolates of
Acinetobacter nosocomialis
Antimicrobial agents
No. (%) of isolates
p
Colistin resistant
(n [ 58)
Colistin susceptible
(n [ 213)
Amikacin 21 (36.2) 46 (21.6) 0.002
Gentamicin 46 (79.3) 57 (26.8) <0.001
Cefotaxime or ceftriaxone 44 (75.9) 145 (68.1) 0.213
Ceftazidime 17 (29.3) 27 (12.7) 0.002
Cefepime or cefpirome 11 (19.0) 22 (10.3) 0.087
Ciproﬂoxacin 0 (0) 14 (6.6) 0.040
Piperacillin–tazobactam 16 (27.6) 32 (15.0) 0.021
Imipenem 23 (39.7) 26 (12.2) <0.001
Meropenem 12 (20.7) 17 (8.0) 0.003
CMI Wang et al. Colistin-resistant Acinetobacter nosocomialis bacteraemia 761observed. Multivariate analysis indicated that COPD (OR 3.04;
95% CI 1.45–6.37; p 0.003) was the only factor independently
associated with ColRAN bacteraemia (Table 3).
ColRAN isolates were more resistant to all tested antimi-
crobial agents except for ciproﬂoxacin, and these differences
were statistically signiﬁcant (p < 0.05) for amikacin, genta-
micin, ceftazidime, piperacillin–tazobactam, imipenem, and
meropenem (Table 4). For these isolates, the MIC50 and
MIC90 of colistin were 4 mg/L and 8 mg/L, respectively (data
not shown).
We performed PFGE with a cluster analysis of all 58 Col-
RAN isolates (Fig. 1). There were 16 pulsotypes (A–P), based
on a threshold of 80% similarity. Pulsotypes A (n = 22) and L
(n = 19) were the most common. The number of cases of
ColRAN bacteraemia in each year is shown in Fig. 2. Conju-
gation experiments failed to prove that colistin resistance genes
could be transferred from ColRAN to ColSAB and ColSAN.TABLE 3. Multivariate analysis of independent risk factors for
bacteraemia caused by colistin-resistant Acinetobacter
nosocomialis
Variables
Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
Acquired in an ICU 4.38 (2.23–8.60) <0.001 — —
Chronic obstructive
pulmonary disease
3.66 (1.84–7.30) <0.001 3.04 (1.45–6.37) 0.003
Previous exposure to
antipseudomonal β-lactam
3.03 (1.61–5.70) <0.001 — —
Previous exposure to
non-antipseudomonal
β-lactam
1.76 (0.94–3.30) 0.077 — —
Hospitalization duration
prior to culture
1.01 (1.00–1.01) 0.005 — —
Respiratory failure under
mechanical ventilationa
4.15 (2.17–7.94) <0.001 — —
ICU, intensive-care unit.
aUnder mechanical ventilation support for >48 h prior to bacteraemia onset.
Clinical Microbiology and Infection © 2015 European Society of Clinical MicrobiologyDiscussionThe results of this study revealed signiﬁcant differences be-
tween the clinical characteristics of patients with ColRAN and
ColSAN bacteraemia and the antimicrobial resistance patterns
of the ColRAN and ColSAN clinical isolates. In patients with no
history of colistin exposure, COPD was the only clinical factor
independently associated with ColRAN bacteraemia. PFGE
analysis of all 58 ColRAN isolates disclosed the presence of 16
pulsotypes, and 41 (70.7%) of the isolates were found to be
pulsotype A or L. Conjugation experiments failed to prove that
colistin resistance could be transferred to ColSAB and ColSAN.
Colistin was introduced to Taiwan in September 2007, ac-
cording to the Taiwan National Health Insurance Research
Database (data not shown). Four of our patients acquired
ColRAN after that time; none of them had been referred from
other hospitals, but rather acquired the bacteria during hospi-
talization at the T-VGH. However, this does not conﬁrm that
the patients had not been exposed to colistin prior to their
hospitalization. After exclusion of these four patients, the
analysis revealed that COPD remained an independent factor
associated with the acquisition of ColRAN bacteraemia in our
study (data not shown).
Previous studies have proposed COPD as a risk factor for
colonization and infection by non-fermenting Gram-negative
bacilli and multidrug-resistant bacteria [21–24]. Several factors
might explain these observations, including the prior use of
antibiotics [21], use of mechanical ventilation [22], use of ste-
roids [23], and impaired lung function [23,24]. However, the
present study indicated that previous antibiotic use, mechanical
ventilation and steroid use were not independently related to
the presence of ColRAN bacteraemia. In COPD patients, the
deterioration of lung function is associated with chronic
inﬂammation, impaired mucociliary clearance in the lower air-
ways, impaired local immune response, and disruption of the
lung parenchyma [23,24]. Previous research has demonstratedand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 758–764
FIG. 1. Pulsed-ﬁeld gel electrophoresis of 58 isolates of colistin-resistant Acinetobacter nosocomialis indicated two major clones, pulsotypes A and L.
FIG. 2. Year-wise distribution of cases of colistin-resistant Acinetobacter
nosocomialis bacteraemia.
762 Clinical Microbiology and Infection, Volume 21 Number 8, August 2015 CMIthat ColRAB isolates show signiﬁcantly altered cellular
morphology relative to ColSAB [25], including lipopolysaccha-
ride deﬁciency, which might compromise virulence [26]. Hos-
pitalized patients with different comorbidities might be similarly
exposed to ColRAN, but the impaired virulence of this bacte-
rium might only allow it to colonize and cause bacteraemia in
COPD patients with impaired lung immunity. It remains to be
investigated whether ColRAN undergoes cellular morphology
alterations, as previously described for ColRAB [8,25], to make
it better able to colonize the lung parenchyma of COPD
patients.
In our study, patients with ColRAN bacteraemia had more
severe illness than patients with ColSAN bacteraemia. SimilarClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 758–764
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antimicrobial therapy. However, the two groups did not differ
signiﬁcantly in terms of mortality. Among the patients with
bacteraemic pneumonia, those with ColRAN and ColSAN had
similar mortality rates and durations of mechanical ventilation
use. These ﬁndings are consistent with previous studies on
ColRAB [10,11], and suggest that increased resistance to
colistin does not affect the virulence of these species.
Inappropriate colistin use is a well-known cause of colistin
resistance [7–13]. To delineate the predisposing factors for
the acquisition of ColRAN other than colistin use, we con-
ducted this retrospective study. We found that previous
antibiotic use or exposure to a select class of anti-
pseudomonal agents was not independently associated with
ColRAN bacteraemia. This result is concordant with previous
studies on ColRAB [8–11].
There is no standard therapeutic guideline for the manage-
ment of colistin-resistant Acinetobacter infections. Some studies
have described the use of combination therapies, such as
colistin–rifampicin or colistin–carbapenem, for the treatment
of ColRAB infections [10,27]. Previous research has indicated
high susceptibility of ColRAB to ciproﬂoxacin [28]; similarly, we
found that all 58 ColRAN isolates were susceptible to cipro-
ﬂoxacin. Further research is needed to elucidate the relation-
ship between colistin resistance and ciproﬂoxacin susceptibility
in Acinetobacter species.
According to our molecular epidemiological examination of
ColRAN isolates, there was dissemination of two major clones
(pulsotypes A and L) during the study period, but a hospital
outbreak was less likely, as none of the isolates clustered within
a short period of time. Non-baumannii Acinetobacter species,
including A. nosocomialis, might be reservoirs or recipients of
resistance determinants from A. baumannii. For example, the
plasmid-borne blaOXA-82 gene, which contains the upstream
insertion sequence ISAba1 that contributes to carbapenem
resistance, is transmittable between A. baumannii and
A. nosocomialis [19,29]. However, our conjugation experiments
showed that ColRAN isolates did not transfer colistin resis-
tance to A. baumannii.
This study had limitations that are inherent to retrospective
studies, including inconsistencies in patient care and variability
in patient backgrounds. The large number of patients with
A. nosocomialis bacteraemia was a major strength of this study.
Another strength is our use of a multivariate analysis to assess
clinical variables that were independently and signiﬁcantly
associated with ColRAN bacteraemia.
In conclusion, COPD was an independent risk factor for the
acquisition of ColRAN bacteraemia in patients without previ-
ous exposure to colistin. Although ColRAN bacteraemia was
associated with more severe illness than ColSAN bacteraemia,Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiologypatients with these two infections had similar 14-day, 28-day
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